title: Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population.
abstract: Disseminated Mycobacterium avium complex (MAC) infection is common in persons with advanced HIV infection and can be prevented by prophylactic use of rifabutin; however, routine prophylaxis is costly and incompletely effective. Chronic anemia is a common manifestation of MAC infection. We conducted a retrospective population study of the annual incidence of MAC bacteremia and blood transfusion for anemia in a regional HIV-positive population before and after the introduction of rifabutin to determine the effect of MAC prophylaxis on the incidence of transfusion-requiring anemia. The HIV-infected patient populations in 1992 and 1993 were comparable in number, severity of immunodeficiency, and zidovudine (ZDV) use. The use of rifabutin for MAC prophylaxis for those with CD4 T-lymphocyte counts < 100/microl increased from 17.2% in 1992 to 33.7% in 1993 (p < 0.001), whereas diagnostic surveillance for MAC bacteremia was stable. In 1993, there was a decrease in the number of HIV-infected persons from whom MAC was isolated (10 vs. 26, p = 0.004), and a significant decrease in the number of patients transfused for anemia (15 vs. 35, p = 0.002), number of transfusion episodes, and numbers of units transfused, associated with significant cost and resource savings. Adoption of MAC prophylaxis was followed by a significant decrease in the number of diagnosed MAC infections and in transfusion requirements in an HIV-positive population with sustained surveillance and similar levels of immunodeficiency, which may represent a health and economic benefit of effective [correction of defective] MAC prophylaxis in a population at risk.
authors.affiliation: Division of General Medicine, Ottawa General Hospital, University of Ottawa, Ontario, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Kravcik
authors.forename: B W
authors.initials: BW
authors.lastname: Toye
authors.forename: K
authors.initials: K
authors.lastname: Fyke
authors.forename: N
authors.initials: N
authors.lastname: Hawley-Foss
authors.forename: D
authors.initials: D
authors.lastname: Fillion
authors.forename: J A
authors.initials: JA
authors.lastname: Yurack
authors.forename: D W
authors.initials: DW
authors.lastname: Cameron
mesh_terms: D000740:Anemia / Q000628:therapy; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D001803:Blood Transfusion; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D012189:Retrospective Studies; D017828:Rifabutin / Q000627:therapeutic use*
chemical_list: D000904:Antibiotics, Antitubercular; D017828:Rifabutin